NT-proBNP or Self-Reported Functional Capacity in Estimating Risk of Cardiovascular Events After Noncardiac Surgery
Importance: Nearly 16 million surgical procedures are conducted in North America yearly, and postoperative cardiovascular events are frequent. Guidelines suggest functional capacity or B-type natriuretic peptides (BNP) to guide perioperative management. Data comparing the performance of these approaches are scarce.
Objective: To compare the addition of either N-terminal pro-BNP (NT-proBNP) or self-reported functional capacity to clinical scores to estimate the risk of major adverse cardiac events (MACE).
Design, Setting, and Participants: This cohort study included patients undergoing inpatient, elective, noncardiac surgery at 25 tertiary care hospitals in Europe between June 2017 and April 2020. Analysis was conducted in January 2023. Eligible patients were either aged 45 years or older with a Revised Cardiac Risk Index (RCRI) of 2 or higher or a National Surgical Quality Improvement Program, Risk Calculator for Myocardial Infarction and Cardiac (NSQIP MICA) above 1%, or they were aged 65 years or older and underwent intermediate or high-risk procedures.
Exposures: Preoperative NT-proBNP and the following self-reported measures of functional capacity were the exposures: (1) questionnaire-estimated metabolic equivalents (METs), (2) ability to climb 1 floor, and (3) level of regular physical activity.
Main Outcome and Measures: MACE was defined as a composite end point of in-hospital cardiovascular mortality, cardiac arrest, myocardial infarction, stroke, and congestive heart failure requiring transfer to a higher unit of care.
Results: A total of 3731 eligible patients undergoing noncardiac surgery were analyzed; 3597 patients had complete data (1258 women [35.0%]; 1463 (40.7%) aged 75 years or older; 86 [2.4%] experienced a MACE). Discrimination of NT-proBNP or functional capacity measures added to clinical scores did not significantly differ (Area under the receiver operating curve: RCRI, age, and 4MET, 0.704; 95% CI, 0.646-0.763; RCRI, age, and 4MET plus floor climbing, 0.702; 95% CI, 0.645-0.760; RCRI, age, and 4MET plus physical activity, 0.724; 95% CI, 0.672-0.775; RCRI, age, and 4MET plus NT-proBNP, 0.736; 95% CI, 0.682-0.790). Benefit analysis favored NT-proBNP at a threshold of 5% or below, ie, if true positives were valued 20 times or more compared with false positives. The findings were similar for NSQIP MICA as baseline clinical scores.
Conclusions and relevance: In this cohort study of nearly 3600 patients with elevated cardiovascular risk undergoing noncardiac surgery, there was no conclusive evidence of a difference between a NT-proBNP-based and a self-reported functional capacity-based estimate of MACE risk.
Trial Registration: ClinicalTrials.gov Identifier: NCT03016936.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
JAMA network open - 6(2023), 11 vom: 01. Nov., Seite e2342527 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lurati Buse, Giovanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 16.11.2023 Date Revised 16.11.2023 published: Electronic ClinicalTrials.gov: NCT03016936 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamanetworkopen.2023.42527 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36430586X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36430586X | ||
| 003 | DE-627 | ||
| 005 | 20231226095147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamanetworkopen.2023.42527 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM36430586X | ||
| 035 | |a (NLM)37938844 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lurati Buse, Giovanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NT-proBNP or Self-Reported Functional Capacity in Estimating Risk of Cardiovascular Events After Noncardiac Surgery |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.11.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03016936 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: Nearly 16 million surgical procedures are conducted in North America yearly, and postoperative cardiovascular events are frequent. Guidelines suggest functional capacity or B-type natriuretic peptides (BNP) to guide perioperative management. Data comparing the performance of these approaches are scarce | ||
| 520 | |a Objective: To compare the addition of either N-terminal pro-BNP (NT-proBNP) or self-reported functional capacity to clinical scores to estimate the risk of major adverse cardiac events (MACE) | ||
| 520 | |a Design, Setting, and Participants: This cohort study included patients undergoing inpatient, elective, noncardiac surgery at 25 tertiary care hospitals in Europe between June 2017 and April 2020. Analysis was conducted in January 2023. Eligible patients were either aged 45 years or older with a Revised Cardiac Risk Index (RCRI) of 2 or higher or a National Surgical Quality Improvement Program, Risk Calculator for Myocardial Infarction and Cardiac (NSQIP MICA) above 1%, or they were aged 65 years or older and underwent intermediate or high-risk procedures | ||
| 520 | |a Exposures: Preoperative NT-proBNP and the following self-reported measures of functional capacity were the exposures: (1) questionnaire-estimated metabolic equivalents (METs), (2) ability to climb 1 floor, and (3) level of regular physical activity | ||
| 520 | |a Main Outcome and Measures: MACE was defined as a composite end point of in-hospital cardiovascular mortality, cardiac arrest, myocardial infarction, stroke, and congestive heart failure requiring transfer to a higher unit of care | ||
| 520 | |a Results: A total of 3731 eligible patients undergoing noncardiac surgery were analyzed; 3597 patients had complete data (1258 women [35.0%]; 1463 (40.7%) aged 75 years or older; 86 [2.4%] experienced a MACE). Discrimination of NT-proBNP or functional capacity measures added to clinical scores did not significantly differ (Area under the receiver operating curve: RCRI, age, and 4MET, 0.704; 95% CI, 0.646-0.763; RCRI, age, and 4MET plus floor climbing, 0.702; 95% CI, 0.645-0.760; RCRI, age, and 4MET plus physical activity, 0.724; 95% CI, 0.672-0.775; RCRI, age, and 4MET plus NT-proBNP, 0.736; 95% CI, 0.682-0.790). Benefit analysis favored NT-proBNP at a threshold of 5% or below, ie, if true positives were valued 20 times or more compared with false positives. The findings were similar for NSQIP MICA as baseline clinical scores | ||
| 520 | |a Conclusions and relevance: In this cohort study of nearly 3600 patients with elevated cardiovascular risk undergoing noncardiac surgery, there was no conclusive evidence of a difference between a NT-proBNP-based and a self-reported functional capacity-based estimate of MACE risk | ||
| 520 | |a Trial Registration: ClinicalTrials.gov Identifier: NCT03016936 | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a pro-brain natriuretic peptide (1-76) |2 NLM | |
| 700 | 1 | |a Larmann, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Gillmann, Hans-Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Kotfis, Katarzyna |e verfasserin |4 aut | |
| 700 | 1 | |a Ganter, Michael T |e verfasserin |4 aut | |
| 700 | 1 | |a Bolliger, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Filipovic, Miodrag |e verfasserin |4 aut | |
| 700 | 1 | |a Guzzetti, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Chammartin, Frédérique |e verfasserin |4 aut | |
| 700 | 1 | |a Mauermann, Eckhard |e verfasserin |4 aut | |
| 700 | 1 | |a Ionescu, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Szczeklik, Wojciech |e verfasserin |4 aut | |
| 700 | 1 | |a De Hert, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Beck-Schimmer, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Howell, Simon J |e verfasserin |4 aut | |
| 700 | 0 | |a METREPAIR NTproBNP Subcohort Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Kemper, Johann |e investigator |4 oth | |
| 700 | 1 | |a Kohaupt, Lena |e investigator |4 oth | |
| 700 | 1 | |a Witzler, Jette |e investigator |4 oth | |
| 700 | 1 | |a Tuzhikov, Michael |e investigator |4 oth | |
| 700 | 1 | |a Roth, Sebastian |e investigator |4 oth | |
| 700 | 1 | |a Stroda, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a MPembele, Rene |e investigator |4 oth | |
| 700 | 1 | |a Schultze, Cornelia |e investigator |4 oth | |
| 700 | 1 | |a Verbarg, Nele |e investigator |4 oth | |
| 700 | 1 | |a Gehrke, Christian |e investigator |4 oth | |
| 700 | 1 | |a Espeter, Florian |e investigator |4 oth | |
| 700 | 1 | |a Russe, Benedikt |e investigator |4 oth | |
| 700 | 1 | |a Weigand, Markus A |e investigator |4 oth | |
| 700 | 1 | |a Pirzer, Raphael |e investigator |4 oth | |
| 700 | 1 | |a Rach, Patric Rene |e investigator |4 oth | |
| 700 | 1 | |a Neumann, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Sponhol, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Carollo, Melissa |e investigator |4 oth | |
| 700 | 1 | |a Toso, Fiorenza |e investigator |4 oth | |
| 700 | 1 | |a Bacuzzi, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Servén, Marta G |e investigator |4 oth | |
| 700 | 1 | |a Artigas Soler, Anna |e investigator |4 oth | |
| 700 | 1 | |a Basso, Morena |e investigator |4 oth | |
| 700 | 1 | |a Peig Font, Anna |e investigator |4 oth | |
| 700 | 1 | |a Torrente-Perez, Jara |e investigator |4 oth | |
| 700 | 1 | |a Fores, Maria Isabel |e investigator |4 oth | |
| 700 | 1 | |a Bubenek-Turconi, Serban |e investigator |4 oth | |
| 700 | 1 | |a Vale, Liana |e investigator |4 oth | |
| 700 | 1 | |a Wanner, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Djurdjevic, Mirjana |e investigator |4 oth | |
| 700 | 1 | |a Nuth, Sandra |e investigator |4 oth | |
| 700 | 1 | |a Seeberger, Esther |e investigator |4 oth | |
| 700 | 1 | |a Kamber, Firmin |e investigator |4 oth | |
| 700 | 1 | |a Gerber, Thomas Jan |e investigator |4 oth | |
| 700 | 1 | |a Schneebeli, Daniela |e investigator |4 oth | |
| 700 | 1 | |a Grape, Sina |e investigator |4 oth | |
| 700 | 1 | |a Bollen Pinto, Bernardo |e investigator |4 oth | |
| 700 | 1 | |a Karolak, Igor |e investigator |4 oth | |
| 700 | 1 | |a Lechowicz, Kacper |e investigator |4 oth | |
| 700 | 1 | |a Drozdzal, Sylwester |e investigator |4 oth | |
| 700 | 1 | |a Kluzik, Anna |e investigator |4 oth | |
| 700 | 1 | |a van Lier, Felix |e investigator |4 oth | |
| 700 | 1 | |a Carrao, Andre |e investigator |4 oth | |
| 700 | 1 | |a Ribeiro, Daniela |e investigator |4 oth | |
| 700 | 1 | |a Santos, Nuno |e investigator |4 oth | |
| 700 | 1 | |a Drummond, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Belskii, Vladislav |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA network open |d 2018 |g 6(2023), 11 vom: 01. Nov., Seite e2342527 |w (DE-627)NLM289300517 |x 2574-3805 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2023 |g number:11 |g day:01 |g month:11 |g pages:e2342527 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamanetworkopen.2023.42527 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2023 |e 11 |b 01 |c 11 |h e2342527 | ||